FDA halts DBV's peanut allergy trial

The US health authority has put a partial clinical hold on the company’s peanut allergy phase III trial until certain study changes have been made.

DBV's journey towards the peanut allergy market has just been made more difficult by the FDA | Photo: Andrew Kelly/REUTERS / X02844

Just few weeks after French DBV Technologies could celebrate having finished the protocol for its peanut allergy phase III trial, the US Food and Drug Administration (FDA) has found some flaws, and is putting the study on hold, industry media Fierce Biotech reports.

The FDA now requires that DBV makes changes to the study before allowing it to move ahead. One demand is that DBV enroll more patients.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs